532523 announcements Biocon Ltd. announcements and dividends declared BSE
Biocon Ltd. Complete list of announcements declared & dividend announcements by Biocon Ltd. 532523
Biocon Ltd. 532523 listed on BSE and deals inAnnouncements and dividends declared by Biocon Ltd. 532523
Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy
Biocon Biologics Ltd has achieved a significant milestone. It has secured marketing authorizations in the UK for Vevzuo and Evfraxy. These are biosimilars of Denosumab. Vevzuo addresses skeletal events in adults with advanced malignancies. Evfraxy treats o
Announcement as on 07 July 2025
Biocon biologics receives European Commission approval for Vevzuo, Evfraxy Denosumab biosimilars for bone diseases
Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars, used to treat various bone diseases. Vevzuo addresses bone complications in cancer patients and giant cell tumors, while Evfraxy
Announcement as on 03 July 2025
Karnataka CM's remarks on covid vaccines 'factually incorrect,' says Biocon chief Kiran Mazumdar-Shaw
Kiran Mazumdar-Shaw refuted Karnataka CM Siddaramaiah's claim. Siddaramaiah linked covid-19 vaccines to heart attack deaths in Hassan. Shaw stated the vaccines followed rigorous safety protocols. She said the vaccines saved lives. The Union Health Ministry
Announcement as on 03 July 2025
Biocon eyes Canadian bonanza from generics of weight-loss 'super-drugs' Ozempic and Wegovy
Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canada, where patents expire next year. Managing Director Siddharth Mittal sees Canada as a prime opportunity, aiming for
Announcement as on 02 July 2025
Biocon drops plan to launch weight-loss drugs in China, executive says
Biocon has scrapped its plans to introduce generic versions of Novo Nordisk's Ozempic and Wegovy in China, citing intense local competition. The decision comes as numerous Chinese drugmakers are developing generics and biosimilars ahead of the semaglutide
Announcement as on 27 June 2025
Announcements by Biocon Ltd. first page | Next page | Prev page |
532523 Biocon Ltd. current price & indicator signals
Recent prices of 532523 Biocon Ltd. are as follows: Daily volume is divided by 10 day averaged volume
| Date | Close | Range | Change % | Volume |
| 18 Fri Sep 2026 | 385.00 | 379.50 to 388.80 | 1.32% | 0.05 times |
| 17 Thu Sep 2026 | 380.00 | 370.45 to 381.75 | 1.59% | 0.03 times |
| 16 Wed Sep 2026 | 374.05 | 374.00 to 383.70 | -1.82% | 0.04 times |
| 15 Tue Sep 2026 | 381.00 | 381.00 to 392.50 | -2.55% | 0.06 times |
| 11 Fri Sep 2026 | 390.95 | 384.80 to 396.65 | 0.24% | 0.05 times |
| 10 Thu Sep 2026 | 390.00 | 388.65 to 397.50 | -1.27% | 0.06 times |
| 09 Wed Sep 2026 | 395.00 | 393.10 to 403.95 | 0.62% | 9.45 times |
| 08 Tue Sep 2026 | 392.55 | 390.90 to 399.50 | -0.24% | 0.07 times |
| 07 Mon Sep 2026 | 393.50 | 388.70 to 397.25 | -0.94% | 0.16 times |
| 04 Fri Sep 2026 | 397.25 | 396.50 to 404.80 | -1.18% | 0.04 times |
| 03 Thu Sep 2026 | 402.00 | 400.60 to 405.70 | 0.17% | 0.03 times |
| 02 Wed Sep 2026 | 401.30 | 397.85 to 402.00 | 0.01% | 0.28 times |
Videos related to: 532523 announcements Biocon Ltd. announcements and dividends declared BSE
Hindi Video Most Important Stock Market Video. No Success Without This Formula
Hindi Video What Is Needed To Succeed In Stock Markets
- BSE Screeners
- BSE Daily Screener
- BSE Weekly Screener
- BSE Monthly Screener
- Support & Resistance
- BSE Shares Near Support
- BSE Shares Near Resistance


